IRCT20220409054467N3 IRCT 2022-08-15 Tehran University of Medical Sciences Effects of Adalimumab in Iranian Pediatric with Inflammatory Bowel Disease Effects of Adalimumab in Iranian Pediatric with Inflammatory Bowel Disease 2022-08-23 anticipated 25 Complete https://irct.ir/trial/65147 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 3 Inflammatory bowel disease. Intervention group: Administration of adalimumab (40 mg/0.8 ml) which is injected in patients weighing less than 40 kg based on the following dose: 80 mg first, 40 mg two weeks later, 20 mg two weeks after the second dose and then depending on the response, 20 mg should be taken subcutaneously once every one or two weeks. Also, subcutaneous injection was performed for people weighing more than 40 kg based on the following dose: first 160 mg, two weeks later 80 mg, two weeks after the second dose 40 mg, then according to the response, 40 mg is injected every one or two weeks.. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information